Provenge Immunotherapy Increases Overall Survival in African-American Men with Metastatic Prostate Cancer

Provenge Immunotherapy Increases Overall Survival in African-American Men with Metastatic Prostate Cancer
African-American men with metastatic castrate-resistant prostate cancer survive significantly longer than Caucasian men when treated with Provenge, according to new findings from Dendreon’s PROCEED registry, which is following patients’ outcomes in a real-world treatment setting. The new results were recently presented at the 112th American Urological Association (AUA) Annual Meeting held May 12-16 in Boston. Provenge is the only

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

3 comments

  1. Herschell Atkinson says:

    Is there any website I can go to to get updated results of men that took the Provenge protocol and then followed up with Xtandi.
    I did provenge in November 2015 and then started Xtandi in January 2016.

Leave a Comment

Your email address will not be published. Required fields are marked *